Atea Pharmaceuticals, Inc. Logo

Atea Pharmaceuticals, Inc.

Clinical-stage biopharma developing oral antiviral therapies for serious viral diseases.

AVIR | US

Overview

Corporate Details

ISIN(s):
US04683R1068
LEI:
Country:
United States of America
Address:
225 FRANKLIN STREET, 2110 BOSTON

Description

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company leverages its expertise in virology, medicinal chemistry, and biology to develop direct-acting antivirals for single-stranded ribonucleic acid (ssRNA) viruses. Atea's lead program is a combination regimen of bemnifosbuvir (a nucleotide analog polymerase inhibitor) and ruzasvir (an NS5A inhibitor) for the treatment of Hepatitis C Virus (HCV). This oral, pan-genotypic regimen is currently in a global Phase 3 development program, aiming to address unmet medical needs for patients with HCV.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Atea Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Atea Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Atea Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aldeyra Therapeutics, Inc. Logo
Develops medications for immune-mediated ocular and systemic diseases.
United States of America
ALDX
Alector, Inc. Logo
Clinical-stage biotech using immuno-neurology to treat neurodegenerative diseases.
United States of America
ALEC
ALK-Abelló Logo
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
Denmark
ALK
Alkaloid AD Logo
Manufactures generic pharmaceuticals, cosmetics, and chemical products.
North Macedonia
ALK
Alkermes plc. Logo
Develops and commercializes medicines for central nervous system (CNS) diseases.
United States of America
ALKS
Allarity Therapeutics, Inc. Logo
A clinical-stage biopharma using diagnostics to develop targeted cancer therapies.
United States of America
ALLR
ALLERGY THERAPEUTICS PLC Logo
Immunology company developing aluminum-free vaccines and therapies for allergies.
United Kingdom
AGY
Alligator Bioscience Logo
Clinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Sweden
ATORX
Allogene Therapeutics, Inc. Logo
Develops off-the-shelf allogeneic CAR T therapies for cancer and autoimmune diseases.
United States of America
ALLO
Almirall S.A. Logo
Global biopharmaceutical company specializing in medical dermatology and skin health.
Spain
ALM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.